Leap Therapeutics Inc (NASDAQ:LPTX) shares reached a new 52-week low during trading on Monday . The stock traded as low as $4.30 and last traded at $4.45, with a volume of 100 shares changing hands. The stock had previously closed at $4.36.
Several research firms have commented on LPTX. Zacks Investment Research raised Leap Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a research report on Tuesday, July 17th. ValuEngine downgraded Leap Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. Finally, HC Wainwright set a $13.00 target price on Leap Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 23rd.
The company has a market cap of $64.10 million, a price-to-earnings ratio of -1.31 and a beta of 2.11.
Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Wednesday, August 8th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Sell-side analysts anticipate that Leap Therapeutics Inc will post -2.18 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in shares of Leap Therapeutics by 24.7% during the second quarter. Renaissance Technologies LLC now owns 112,467 shares of the company’s stock valued at $1,012,000 after acquiring an additional 22,247 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Leap Therapeutics by 178.0% during the second quarter. Point72 Asset Management L.P. now owns 75,888 shares of the company’s stock valued at $683,000 after acquiring an additional 48,588 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Leap Therapeutics by 39,223.3% during the first quarter. JPMorgan Chase & Co. now owns 40,503 shares of the company’s stock valued at $336,000 after acquiring an additional 40,400 shares in the last quarter. DRW Securities LLC acquired a new stake in shares of Leap Therapeutics during the second quarter valued at about $347,000. Finally, Creative Planning acquired a new stake in shares of Leap Therapeutics during the second quarter valued at about $144,000. Institutional investors own 18.03% of the company’s stock.
WARNING: “Leap Therapeutics (LPTX) Sets New 12-Month Low at $4.30” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/05/leap-therapeutics-lptx-sets-new-12-month-low-at-4-30.html.
Leap Therapeutics Company Profile (NASDAQ:LPTX)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Story: What is a stock buyback?
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.